Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection

Clinical Reviews in Allergy and Immunology

Volumn 32, Issue 1, 2007, Pages 57-65

  Warger, Tobias ^a   Rechtsteiner, Gerd ^a   Schmid, Beate ^a   Osterloh, Philipp ^a   Schild, Hansjörg ^a   Radsak, Markus P ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Epitope; Imiquimod; T cell; Toll like receptor ligand; Transcutaneous immunization; Tumor

Indexed keywords

EPITOPE; IMIQUIMOD; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FGK 45; OVALBUMIN; POLYPEPTIDE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; INOCULATION; MEMORY T LYMPHOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; THYMOMA; TREATMENT OUTCOME;

EID: 34247139249     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02686082     Document Type: Conference Paper

References (30)

1. Danaei, G., Vander, H. S., Lopez, A. D., Murray, C. J., and Ezzati, M. (2005), Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366, 1784-1793.
2. Kaech, S. M., Wherry, E. J., and Ahmed R. (2002), Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251-262.
3. Dudley, M. E. and Rosenberg, S. A. (2003), Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3, 666-675.
4. Dudley, M. E., Nishimura, M. I., Holt, A. K., and Rosenberg, S. A. (1999), Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J. Immunother. 22, 288-298.
5. Rosenberg, S. A., Yang, J. C., and Restifo, N. P. (2004), Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915.
6. Wagner, H., Kronke, M., Solbach, W., Scheurich, P., Rollinghoff, M., and Pfizenmaier, K. (1982), Murine T cell subsets and interleukins: relationships between cytotoxic T cells, helper T cells and accessory cells. Clin. Haematol. 11, 607-630.
7. Castellino, F. and Germain, R. N. (2006), Cooperation Between CD4(+) and CD8(+) T Cells: When, Where, and How (*). Annu Rev Immunol 24, 519-540.
8. Butz, E. A. and Bevan, M. J. (1998), Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 8, 167-175.
9. Ridge, J. P., Di Rosa, F., and Matzinger, P. (1998), A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478.
10. Grewal, I. S. and Flavell, R. A. (1998), CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135.
11. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R., and Melief, C. J. (1998), T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483.
12. Toes, R. E., Schoenberger, S. P., van der Voort, EI., Offringa, R., and Melief, C. J. (1998), CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 10, 443-448.
13. Rechtsteiner, G., Warger, T., Osterloh, P., Schild, H., and Radsak, M. P. (2005), Cutting Edge: Priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174, 2476-2480.
14. Thomsen, L. L., Topley, P., Daly, M. G., Brett, S. J., and Tite, J. P. (2004), Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22, 1799-1809.
15. Glenn, G. M., Taylor, D. N., Li, X., Frankel, S., Montemarano, A., and Alving, C. R. (2000), Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6, 1403-1406.
16. Romani, N., Koide, S., Crowley, M., et al. (1989), Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J. Exp. Med. 169, 1169-1178.
17. Suzuki, H., Wang, B., Shivji, G. M., et al. (2000), Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest Dermatol. 114, 135-141.
18. Matzinger, P. (2002), The danger model: a renewed sense of self, Science 296, 301-305.
19. Belyakov, I. M., Hammond, S. A., Ahlers, J. D., Glenn, G. M., and Berzofsky, J. A. (2004), Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113, 998-1007.
20. Shackleton, M., Davis, I. D., Hopkins, W., et al. (2004), The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4, 9.
21. Itoh, T. and Celis, E. (2005), Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J. Immunother. 28, 430-437.
22. Antia, R., Ganusov, V. V., and Ahmed, R. (2005), The role of models in understanding CD8+ T-cell memory. Nat Rev Immunol 5, 101-111.
23. Pulendran, B. and Ahmed, R. (2006), Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849-863.
24. Grewal, I. S. and Flavell, R. A. (1996), The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 153, 85-106.
25. Ahonen, C. L., Doxsee, C. L., McGurran, S. M., et al. (2004), Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199, 775-784.
26. Diehl, L., den Boer, A. T., Schoenberger, S. P., et al. (1999), CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5, 774-779.
27. Rosenberg, S. A. (2001), Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
28. Campoli, M., Ferrone, S., Zea, A. H., Rodriguez, P. C., and Ochoa, A. C. (2005), Mechanisms of tumor evasion. Cancer Treat Res 123, 61-88.
29. Merad, M., Hoffmann, P., Ranheim, E., et al. (2004), Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10, 510-517.
30. French, R. R., Chan, H. T., Tutt, A. L., and Glennie, M. J. (1999), CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5, 548-553.